Literature DB >> 21333049

Percutaneous nephrolithotomy: critical analysis of unfavorable results.

Abdulkader Alobaidy1, Abdulla Al-Naimi, Khalid Assadiq, Haidar Alkhafaji, Abdulla Al-Ansari, Ahmed A Shokeir.   

Abstract

OBJECTIVE: To identify the risk factors of unfavorable results of percutaneous nephrolithotomy (PCNL). PATIENTS AND METHODS: A total of 602 patients were subjected to 616 PCNL procedures. Patients were divided into two groups according to the results of treatment. Group 1 with favorable results includes patients who became stone free after a single PCNL procedure without major complications. Group 2 with unfavorable results includes three subgroups: a) Patients who developed major complications, b) Those who required second major intervention to complete stone removal, and c) Patients with residual stones > 4 mm at 3 month. Risk factors for unfavorable outcome were studied by univariate and multivariate analyses.
RESULTS: Unfavorable results were documented in 176 patients (28.6%) due to major complications in 40 (6.5%), need for second intervention in 124 (20%), and presence of residual stones > 4 mm at 3 month in 12 (1.9%). The remaining 440 patients (71.4%) were considered of favorable outcome. Independent risk factors of unfavorable results on multivariate analysis were staghorn stones, multiple stones and stone largest diameter > 50 mm.
CONCLUSION: To optimize the results of PCNL, urologists should consider careful patient selection. Patients with staghorn stones, multiple stones or large stone burden are more susceptible to unfavorable outcome.

Entities:  

Mesh:

Year:  2011        PMID: 21333049

Source DB:  PubMed          Journal:  Can J Urol        ISSN: 1195-9479            Impact factor:   1.344


  2 in total

1.  Stones: can the Guy's stone score predict PNL outcomes?

Authors:  Brian R Matlaga; Elias S Hyams
Journal:  Nat Rev Urol       Date:  2011-07-08       Impact factor: 14.432

Review 2.  Current clinical scoring systems of percutaneous nephrolithotomy outcomes.

Authors:  Wayland J Wu; Zeph Okeke
Journal:  Nat Rev Urol       Date:  2017-05-23       Impact factor: 14.432

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.